Search
Menu
Home
HTB
2017
November
HTB
November 2017
Contents
Editorial
November/December 2017: Volume 18 Number 11/12
i-Base 2017 appeal: we need your help….
Supplements
PrEP for women and PrEP in the UK: new leaflets
Guide to changing treatment: what to do if your viral load rebounds
Conference reports
16th European AIDS Conference (EACS 2017)
Fostemsavir in highly treatment-experienced participants: 24-week phase 3 results
D/C/F/TAF: phase 3 naive results and splitting PI-based FDC tablets
Dolutegravir-based dual therapy as switch option in multiple studies
Switch study shows F/TAF non-inferior to continuing abacavir/3TC
Twice-daily tenofovir alafenamide dose might overcome interaction with rifampicin
No impact on bioavailability of D/C/F/TAF when tablet is split but TAF absorption is reduced if crushed
Studies on dolutegravir and sleep, cardiovascular and CNS side effects, and risk of IRIS
Dolutegravir use in pregnancy: results from small Belgian cohort
No transmissions from breastfeeding in Tanzania cohort from mothers with undetectable viral load
Updated European guidelines launched at EACS 2017
ABX464 nudges viral reservoir but not time to viral rebound
8th International Workshop on HIV & Ageing, 2–3 October 2017, New York
Selected webcasts from 8th HIV and ageing workshop
8th HIV and Ageing Workshop: reports at natap.org
9th IAS Conference on HIV Science (IAS 2017)
Reassuring French data using raltegravir during pregnancy
Earlier ART reduces infant mortality in South Africa but risk of death and loss to follow up still high
Screening HIV positive pregnant women for TB in South Africa increased detection by 10-fold
Antiretrovirals
Long-acting ART for children is a deferred priority despite achievable dosing
Coformulated dolutegravir plus rilpivirine approved in US (Juluca)
Darunavir-based single pill FDC approved in EU (Symtuza)
Treatment access
MSF secures generic hepatitis C treatment at $120 per course
Guidelines
Sexual and reproductive health: draft UK guidelines online for comment (2017)
Side effects
Effects of the anti-inflammatory antibody canakinumab on heart disease and cancer: implications for HIV?
Coinfections and complications
Reducing rates of HIV-related cancer in US from 1996-2012
HIV prevention and transmission
Updates from the PrEP IMPACT study – November 2017
Cure-related research
Estimating the total size of the HIV reservoir
On the web
Conference materials online
Recent peer-review studies
PDFs
November/December 2017: Volume 18 Number 11/12
HTB RSS
Early access
Bipolar disorder in people living with HIV
1 November 2024
Mpox breakthrough cases after two doses of the MVA-BN vaccine
1 November 2024
Management of drug resistance to integrase inhibitors: results from an international perinatal virtual clinic
1 November 2024
All early access reports
Current issues
November 2024
October 2024
September 2024
Back issues
Special report
HTB news: i-Base changes during 2024
1 November 2024
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage
Donate